Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 131

Total 131 documents found.

  •  
  • Takeda's Licensing Activities
  • To deliver innovative new drugs longed for by patients, doctors, and medical service providers as early as possible, Takeda defines its alliance and licensing activities as reinforcement measures to complement its proprietary research and development pipelines.
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2010-2012 Mid-Range Plan Transformation for a New Takeda Vision Takeda's vision is to embody global pharmaceutical leadership through innovation, growth and culture guided by an unwavering commitment to significantly improve the lives of patients. Innovation based on bold leadership in science and medicine resulting in the discovery, development and delivery of high-quality, differentiated products focused on patient needs. Sustainable growth in corporate value by leveraging core therapeutic areas, and an industry-leading pipeline and product portfolio. A culture based on good corporate citizenship that empowers employees through collaboration, inclusion, trust and timely decision making. [Takeda-ism] We, the members of the Takeda G
  • X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Recent progress in stage ■ Discontinued project ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities - 17 - Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license MEPACT Immunostimulant (injection) Non-metastatic osteosarcoma EU Switzerland Approved (Mar 09) Approved (Nov 09) In-house SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with alpha-GI) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Concomitant therapy with Sulfonylurea) Diabetes mellitus (Concomitant therapy with Biguanide) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn
  • ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take
  • 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha
  • XOMA and Takeda Expand Collaboration February 10, 2009
  • BERKELEY, Calif. and Osaka, Japan, February 10, 2009 -- XOMA Ltd. (Nasdaq:XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have expanded their existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. XOMA will receive a $29 million expansion fee and may receive potential milestones and royalties on antibody products. XOMA may incur an estimated $7.5 million for taxes and other costs related to the expanded collaboration.
  • ANNUALREPORT2007 Annual Report 2007 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide The image in the globe: the molecular representation of ramelteon (Rozerem ), insomnia medication This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Aiming to facilitate unde
  • Affymax® and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide™ for Anemia October 19, 2007
  • PALO ALTO, Calif., and Osaka, Japan, October 17, 2007 – Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have been awarded the 2007 Deal of Distinction Award from the Licensing Executives Society of the U.S. and Canada (LES) for their innovative global agreement to develop and commercialize Affymax's lead product candidate, Hematide™, for the treatment of anemia. The Affymax and Takeda collaboration was recognized by the LES as one of the most notable deals in the healthcare industry sector in the last year.
  • Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy August 2, 2007
  • Liestal, Switzerland and Osaka, Japan, August 2, 2007 - Santhera Pharmaceuticals (SWX: SANN, “Santhera”), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”), today announced they have extended their existing commercialization partnership for SNT-MC17 (INN: idebenone) in the European Union and Switzerland to cover the compound's second indication of Duchenne Muscular Dystrophy (DMD). SNT-MC17 is currently in a Phase II clinical trial in Europe for DMD. Results of this trial are expected to be released later this year.
  • CanBas and Takeda to Sign the Collaboration Agreement for Investigational Compounds for Treatment of Cancer March 30, 2007
  • Numazu and Osaka, Japan - March 30, 2007 --- CanBas Co., Ltd. (Numazu, Shizuoka, "CanBas") and Takeda Pharmaceutical Company Limited (Osaka, "Takeda") today announced that both parties signed the collaboration agreement for investiga- tional compounds for treatment of cancer, CBP501 and its backup compounds discovered by CanBas. With this agreement, the world-wide exclusive right for development, manufacturing and marketing is granted to Takeda, while in the U.S. the development and promotion are jointly conducted by both parties.
  • XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development February 28, 2007
  • Berkeley, CA, and Osaka, JAPAN - February 28, 2007 - XOMA Ltd. (Nasdaq: XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006.With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has receivedor is otherwise due approximately $8 million as various collaboration-related payments.

Pages:[1] [2] [3] [4] [5] [6] [7]   Next

Page Top